Scancell Holdings Share News (SCLP)

Scancell Gets Ichor Extension, But Agrees To Waive Options Lock In

Prezzo exec slices off 200,000 shares

Kuldip Sehmi, an Executive Director at Italian restaurant chain Prezzo, on Monday traded in 200,000 shares, reducing his stake to 682,244 shares, equal to 0.29 per cent of the issued share capital. Sehmi, who is responsible for the day to day running of approximately half the Prezzo estate, sold t

DIRECTOR DEALINGS: Scancell Directors Sell Shares

Scancell reports progress across a number of trials

Scancell, which develops novel immunotherapies for the treatment of cancer, on Tuesday revealed that four out of the six evaluable patients treated with either the 2mg or 4mg dose of its SCIB1 drug still remain alive. It said the mean survival time in this group of five Stage IV and one Stage IIIb

Scancell secures Australian patent

Scancell said it had received a patent for its DNA ImmunoBody treatment in Australia. Australia is the first jurisdiction to approve the DNA patent. Scancell said it was an important step to comprehensively protecting the technology. Scancell specialises in treatments to encourage the immune sys

Scancell DNA Immunotherapy Technology Granted Patent In Australia

SABMilller Chairman sells over 11m pounds in shares

Graham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so

Scancell shares healthy following patent approval award in Japan

Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan. The same patent has already been approved in the US, Europe and Australia. Dr Richard Goodfellow, Joint Chief Executive Officer of Scancell, commented: "This

Sector movers: Pharmaceuticals under the weather as AstraZeneca takes a hit

The pharmaceuticals and biotechnology sector was at the bottom of the pile on Thursday after a disappointing set of full-year results from AstraZeneca weighed on share prices. The company, which manufactures drugs to treat range of cardiovascular conditions, reported a 15% fall in revenue at consta

Six month operating loss increases slightly at Scancell

AIM-listed medical company Scancell has published its unaudited interim results for the six month period to October 31st, showing an overall operating loss of 989,981 pounds. This compared to a loss of £941,674 in the corresponding period in 2011. The cash at bank on October 31st was £2.6m compar

Scancell Holdings updates on clinical trial of melanoma vaccine

Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma. The developer of therapeutic cancer vaccines recruited and treated the final patient in the second phase of tests for SCIB1, a DNA ImmunoBody injection. The trial is being cond